Barclays lowered the firm’s price target on Waters to $270 from $288 and keeps an Equal Weight rating on the shares. The analyst previewed the Q3 earnings reports for the life science tools and diagnostics sector and dug into bioprocessing destocking and the risk of National Institutes of Health budget cuts.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on WAT: